4.5 Article

Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease

期刊

NEUROBIOLOGY OF AGING
卷 64, 期 -, 页码 -

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2017.12.012

关键词

Parkinson's disease; SNCA; H50Q; His50Gln

资金

  1. Intramural Research Program of the National Institutes of Health (National Institute of Neurological Disorders and Stroke, National Institute on Aging) [1ZIA-NS003154-2, Z01-AG000949]
  2. National Institute for Health Research University College London Hospitals Biomedical Research Centre
  3. AbbVie
  4. Avid
  5. Biogen
  6. Bristol-Myers Squibb
  7. Covance
  8. GE Healthcare
  9. Genentech
  10. GlaxoSmithKline
  11. Lilly
  12. Lundbeck
  13. Merck
  14. Meso Scale Discovery
  15. Pfizer
  16. Piramal
  17. Roche
  18. Servier
  19. Teva
  20. UCB
  21. Golub Capital
  22. Michael J. Fox Foundation
  23. Canadian Consortium on Neurodegeneration in Aging (CCNA)
  24. France Parkinson's Association
  25. NIH [K02NS080915]
  26. Parkinson's Disease Foundation
  27. EU Joint Programme-Neurodegenerative Disease Research (JPND)

向作者/读者索取更多资源

SNCA missense mutations are a rare cause of autosomal dominant Parkinson's disease (PD). To date, 6 missense mutations in SNCA have been nominated as causal. Here, we assess the frequency of these 6 mutations in public population databases and PD case-control data sets to determine their true pathogenicity. We found that 1 of the 6 reported SNCA mutations, His50Gln, was consistently identified in large population databases, and no enrichment was evident in PD cases compared to controls. These results suggest that His50Gln is probably not a pathogenic variant. This information is important to provide counseling for His50Gln carriers and has implications for the interpretation of His50Gln a-synuclein functional investigations. Published by Elsevier Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据